NITE - Nightstar Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Nightstar Therapeutics plc

10 Midford Place
2nd Floor
London W1T 5BJ
United Kingdom
44 20 7062 2777

Full Time Employees47

Key Executives

NameTitlePayExercisedYear Born
Mr. David FellowsCEO & DirectorN/AN/A1957
Mr. Senthil Vel SundaramChief Financial OfficerN/AN/A1978
Dr. Gregory Scott RobinsonChief Scientific OfficerN/AN/A1959
Brian LuqueSr. Mang. of Investor RelationsN/AN/AN/A
Mr. Seokho Bryan Yoon Esq.Gen. Counsel & Group Sec.N/AN/A1978
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 2/3 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was incorporated in 2017 and is headquartered in London, the United Kingdom.

Corporate Governance

Nightstar Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.